[Effect duration and treatment effectiveness of salmeterol, fenoterol and salbutamol in severe forms of respiratory tract obstruction]
- PMID: 8584522
[Effect duration and treatment effectiveness of salmeterol, fenoterol and salbutamol in severe forms of respiratory tract obstruction]
Abstract
Duration and intensity of bronchodilator action of 0.2 mg Fenoterol, 0.2 mg Salbutamol, and 0.05 mg Salmeterol were investigated in 15 subjects with COPD over a period of 12 hours. Airway resistance and FEV1 were measured and subjective side effects noted. Salbutamol MDI was used as rescue medication. Airway resistance and FEV1 demonstrated significant bronchodilation with all bronchodilator drugs after 15 min and maximum bronchodilation between 1 and 2 hrs. After 3 to 5 hrs. bronchodilator effects of fenoterol and salbutamol are lost by at least 50%, whereas this effect is only seen after 8 to 9.5 hrs. with salmeterol. There were considerable individual differences of the efficacy of all three drugs. However, salmeterol was equally efficaceous, compared to fenoterol and salbutamol, but its duration was at least twice as long. Consequently, rescue medication was used in only about 50% of the cases. Side effects of all substances were comparable. From these data it may be concluded that the efficacy of beta2-adrenergic agonists is comparable, irrespective of the duration of action of a single administration, if repeated administrations are used with short acting substances. In addition, this study confirmed that in individual patients a) the response to beta2-adrenergic agonists is variable and b) that different lung function parameters such as airway resistance and FEV1 may give different results.
Similar articles
-
[Responder and non-responder in the bronchodilator test?].Pneumologie. 1995 Nov;49(11):584-9. Pneumologie. 1995. PMID: 8584530 Clinical Trial. German.
-
Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.Respirology. 2007 Sep;12(5):732-9. doi: 10.1111/j.1440-1843.2007.01132.x. Respirology. 2007. PMID: 17875063 Clinical Trial.
-
[Comparison of bronchodilator effects and site of action of fenoterol and ipratropium in chronic obstructive bronchitis].Rev Mal Respir. 1993;10(1):9-15. Rev Mal Respir. 1993. PMID: 8451502 Clinical Trial. French.
-
Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol.Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. Int J Clin Pharmacol Ther Toxicol. 1992. PMID: 1358833 Review.
-
[Current dosed aerosols in the treatment of obstructive airway diseases. 2. Bronchospasmolytics].Z Arztl Fortbild (Jena). 1984;78(1):5-9. Z Arztl Fortbild (Jena). 1984. PMID: 6231780 Review. German. No abstract available.
Cited by
-
Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD001104. doi: 10.1002/14651858.CD001104.pub2. Cochrane Database Syst Rev. 2006. PMID: 16855959 Free PMC article.
-
Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.Drugs. 2000 Aug;60(2):307-20. doi: 10.2165/00003495-200060020-00005. Drugs. 2000. PMID: 10983735 Review.